Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation

• Published in: Transplantation reviews (Philadelphia, Pa.) Pa.), 2024-07, Vol.38 (3), p.100842, Article 100842
• Main Authors: Xie, Wenmin, Fan, Shupan, Liu, Ruolin, Yan, Wencheng, Su, Chengxin, Zheng, Kaile, Wang, Xuebin, Wang, Zhuo
• Format: Article
• Language: English
• Subjects: Clinical outcomes; Graft Rejection - prevention & control; Graft Survival; Humans; Immunosuppressive Agents - therapeutic use; Intra-patient variability; Kidney Transplantation; Measures; Tacrolimus; Tacrolimus - therapeutic use; Threshold; Treatment Outcome
• ISSN: 0955-470X; 1557-9816; 1557-9816
• DOI: 10.1016/j.trre.2024.100842

Tacrolimus (Tac) is commonly prescribed in solid organ transplantation to prevent immune-mediated damage to the graft. However, its pharmacokinetics show substantial variability between and within patients. Intra-patient variability of tacrolimus (Tac-IPV) has emerged as a novel marker to predict transplant outcomes. Numerous studies report varying associations between Tac-IPV and clinical outcomes, with Tac-IPV measures showing wide discrepancies among these studies. This inconsistency could be a significant factor that influences the various outcomes reported in different studies. Our review comprehensively assesses the relationship between various Tac-IPV measures and their associations with clinical outcomes in transplant patients. A comprehensive literature search was conducted using the PubMed and Embase databases, covering the period from 2004 to March 31, 2023. The search focused on studies that examined the relationship between Tac-IPV and clinical outcomes in kidney transplantation (KT). The inclusion criteria were specific to studies addressing Tac-IPV, including measures such as standard deviation (SD), coefficient of variation (CV), time-weighted coefficient of variability (CV), mean absolute deviation (MAD), and Tac variability score (TVS). Clinical outcomes included the development of de novo donor-specific antibodies (dnDSA), rejection episodes, graft loss, and graft failure. Among the 33 studies that met the inclusion criteria, a notable proportion presented conflicting findings in their assessment of various Tac-IPV measures regarding dnDSA, rejection episodes, graft loss, and graft failure. Most studies have identified a correlation between high Tac-IPV and poor clinical outcomes; however, this relationship is multifactorial. Influencing factors include the metabolic status of KT patients, the timing of Tac-IPV calculations, and the criteria for defining high and low Tac-IPV thresholds, including the size and selection method. CV, MAD, and TWCV are the metrics that are most frequently used to determine Tac-IPV. Additionally, most of the methods for establishing Tac-IPV thresholds typically employ receiver operating characteristic (ROC) curves and median values. It is also notable that studies examining the clinical significance of Tac-IPV often include tacrolimus levels measured six months after kidney transplantation. •The five Tac-IPV measures and many widely used markers of clinical outcomes following kidney transplantation are compil